19th January 2021
Thierry Heles
Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.
19th January 2021
Thierry Heles
Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.
18th January 2021
Liwen-Edison Fu
The Oxford-linked oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.
18th January 2021
Robert Lavine
Johnson & Johnson Innovation – JJDC has co-led the computational pathology technology provider's series C round to take its total funding to $195m.
18th January 2021
Thierry Heles
Atalanta Therapeutics has launched out of UMass with $110m in combined series A and partnership funding to develop therapies for neurodegenerative diseases.
18th January 2021
Thierry Heles
Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.
15th January 2021
Callum Cyrus
The eye disease device developer has raised series B funding to advance research originating from University of Colorado's s Sue Anschutz-Rodgers Eye Center.
13th January 2021
Callum Cyrus
Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.
13th January 2021
Jordan Williams
LifeMine’s chairman and co-founder Rick Klausner has co-led a round that included multiple corporates and pushed the overall equity to $120m.
12th January 2021
Callum Cyrus
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.